NCT07488156

Brief Summary

The Impact of Health Literacy on the Attitudes toward Pharmacological Treatment in Patients with Schizophrenia Spectrum Disorder This interventional study is aimed at:

  • assessing and improving the health literacy and
  • assessing the attitude towards treatment of patients with schizophrenia spectrum disorders while they are admitted to the inpatient psychiatric unit.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
34

participants targeted

Target at P25-P50 for not_applicable

Timeline
18mo left

Started Mar 2026

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress16%
Mar 2026Jan 2028

First Submitted

Initial submission to the registry

November 7, 2025

Completed
4 months until next milestone

Study Start

First participant enrolled

March 1, 2026

Completed
22 days until next milestone

First Posted

Study publicly available on registry

March 23, 2026

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 30, 2027

Expected
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2028

Last Updated

March 23, 2026

Status Verified

March 1, 2026

Enrollment Period

1.4 years

First QC Date

November 7, 2025

Last Update Submit

March 17, 2026

Conditions

Schizophrenia DisorderSchizoaffective DisorderPsychosis

Keywords

Educational interventionsSchizophreniaSchizophrenia spectrum disordersHealth literacy

Outcome Measures

Primary Outcomes (2)

  • Post-intervention KAST (Knowledge About Schizophrenia Test) scores

    This includes an 18-item multiple choice test, with only one correct answer for each item. Scores range from 0 to 100%. Higher scores indicate a higher level of knowledge.

    This will be collected on Day 5 of the study, after the participant has completed both educational sessions.

  • Post-intervention ATT (Attitudes Toward Treatment) scores

    This test includes a total of 20 questions, each ranging from 0 to 10 points. Total score ranges from 0 to 200 points. Higher scores indicate a more favorable attitude towards medications.

    This will be collected on Day 5 of the study, after the participant has completed both educational sessions.

Secondary Outcomes (1)

  • MARS (Medication Adherence Rating Scale) scores

    This questionnaire will be given on a monthly basis in the follow up period, for a total of 12 months.

Study Arms (1)

Patients admitted to the inpatient psychiatric unit with a schizophrenia spectrum disorder diagnosis

EXPERIMENTAL

Patients will be exposed to educational materials in the form of a pamphlet and a video

Behavioral: Educational sessions

Interventions

Educational sessionsBEHAVIORAL

Patients will be given an educational pamphlet with information about schizophrenia spectrum disorders, including prognosis and management options. Following this, they will be allowed to ask the doctor any questions they have pertaining to schizophrenia spectrum disorder. In the second educational session, patients will watch a video containing information about schizophrenia spectrum disorders. Following this, they will be allowed to ask the doctor any questions they have pertaining to this topic.

Patients admitted to the inpatient psychiatric unit with a schizophrenia spectrum disorder diagnosis

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients admitted to the University Medical Center-New Orleans (UMCNO) inpatient behavioral health unit ages 18 and older with a new or previous diagnosis of schizophrenia spectrum disorder outside of substance use disorders
  • Patients must be proficient in English.
  • Patients must have a government issued social security number (required for reimbursement through the university).

You may not qualify if:

  • Patients at UMCNO that are ages 17 or younger
  • Patients with SSD and concomitant intellectual disability, as evidenced by prior documented history on chart review or patients suspected to have intellectual disability or impairment based on clinical interactions
  • Patients with concomitant substance use and documentation of psychosis being resolved after a period of washout and without the use of psychotropic medications
  • Patients unable to complete health literacy assessments, attitude towards treatment assessments, and IQ testing due to severity of symptoms during hospitalization
  • Patients that are not proficient in English
  • Patients that do not have a government issued social security number

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Medical Center

New Orleans, Louisiana, 70112, United States

Location

Related Publications (13)

  • Chan AHY, Horne R, Hankins M, Chisari C. The Medication Adherence Report Scale: A measurement tool for eliciting patients' reports of nonadherence. Br J Clin Pharmacol. 2020 Jul;86(7):1281-1288. doi: 10.1111/bcp.14193. Epub 2020 May 18.

    PMID: 31823381BACKGROUND

  • Kampman O, Lehtinen K, Lassila V, Leinonen E, Poutanen O, Koivisto A. Attitudes towards neuroleptic treatment: reliability and validity of the attitudes towards neuroleptic treatment (ANT) questionnaire. Schizophr Res. 2000 Oct 27;45(3):223-34. doi: 10.1016/s0920-9964(99)00204-2.

    PMID: 11042440BACKGROUND

  • Chan KW, Hui LM, Wong HY, Lee HM, Chang WC, Chen YH. Medication adherence, knowledge about psychosis, and insight among patients with a schizophrenia-spectrum disorder. J Nerv Ment Dis. 2014 Jan;202(1):25-9. doi: 10.1097/NMD.0000000000000068.

    PMID: 24375208BACKGROUND

  • von dem Knesebeck O, Mnich E, Daubmann A, Wegscheider K, Angermeyer MC, Lambert M, Karow A, Harter M, Kofahl C. Socioeconomic status and beliefs about depression, schizophrenia and eating disorders. Soc Psychiatry Psychiatr Epidemiol. 2013 May;48(5):775-82. doi: 10.1007/s00127-012-0599-1. Epub 2012 Oct 10.

    PMID: 23052428BACKGROUND

  • Tsai KY, Chung TC, Lee CC, Chou YM, Su CY, Shen SP, Lin CH, Chou FH. Is low individual socioeconomic status (SES) in high-SES areas the same as low individual SES in low-SES areas: a 10-year follow-up schizophrenia study. Soc Psychiatry Psychiatr Epidemiol. 2014 Jan;49(1):89-96. doi: 10.1007/s00127-013-0716-9. Epub 2013 Jun 2.

    PMID: 23728232BACKGROUND

  • Sharp HC. Vasectomy as a means of preventing procreation in defectives. J Am Med Assoc. 1909 Dec 4;53(23):1897-902. doi: 10.1001/jama.1909.92550230009002e.

    PMID: 12334406BACKGROUND

  • Freimuth VS, Quinn SC, Thomas SB, Cole G, Zook E, Duncan T. African Americans' views on research and the Tuskegee Syphilis Study. Soc Sci Med. 2001 Mar;52(5):797-808. doi: 10.1016/s0277-9536(00)00178-7.

    PMID: 11218181BACKGROUND

  • Hamilton LA, Aliyu MH, Lyons PD, May R, Swanson CL Jr, Savage R, Go RC. African-American community attitudes and perceptions toward schizophrenia and medical research: an exploratory study. J Natl Med Assoc. 2006 Jan;98(1):18-27.

    PMID: 16532974BACKGROUND

  • Cheng HL, Kwan KL, Sevig T. Racial and ethnic minority college students' stigma associated with seeking psychological help: Examining psychocultural correlates. J Couns Psychol. 2013 Jan;60(1):98-111. doi: 10.1037/a0031169.

    PMID: 23356468BACKGROUND

  • Gara MA, Minsky S, Silverstein SM, Miskimen T, Strakowski SM. A Naturalistic Study of Racial Disparities in Diagnoses at an Outpatient Behavioral Health Clinic. Psychiatr Serv. 2019 Feb 1;70(2):130-134. doi: 10.1176/appi.ps.201800223. Epub 2018 Dec 10.

    PMID: 30526340BACKGROUND

  • van Hooijdonk CFM, van der Pluijm M, Bosch I, van Amelsvoort TAMJ, Booij J, de Haan L, Selten JP, Giessen EV. The substantia nigra in the pathology of schizophrenia: A review on post-mortem and molecular imaging findings. Eur Neuropsychopharmacol. 2023 Mar;68:57-77. doi: 10.1016/j.euroneuro.2022.12.008. Epub 2023 Jan 12.

    PMID: 36640734BACKGROUND

  • Alegria M, Chatterji P, Wells K, Cao Z, Chen CN, Takeuchi D, Jackson J, Meng XL. Disparity in depression treatment among racial and ethnic minority populations in the United States. Psychiatr Serv. 2008 Nov;59(11):1264-72. doi: 10.1176/ps.2008.59.11.1264.

    PMID: 18971402BACKGROUND

  • Coleman KJ, Stewart C, Waitzfelder BE, Zeber JE, Morales LS, Ahmed AT, Ahmedani BK, Beck A, Copeland LA, Cummings JR, Hunkeler EM, Lindberg NM, Lynch F, Lu CY, Owen-Smith AA, Trinacty CM, Whitebird RR, Simon GE. Racial-Ethnic Differences in Psychiatric Diagnoses and Treatment Across 11 Health Care Systems in the Mental Health Research Network. Psychiatr Serv. 2016 Jul 1;67(7):749-57. doi: 10.1176/appi.ps.201500217. Epub 2016 Apr 15.

    PMID: 27079987BACKGROUND

Related Links

MeSH Terms

Conditions

SchizophreniaPsychotic Disorders

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 7, 2025

First Posted

March 23, 2026

Study Start

March 1, 2026

Primary Completion (Estimated)

July 30, 2027

Study Completion (Estimated)

January 1, 2028

Last Updated

March 23, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations

US(1)